Friday, Jul 24, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

HEALTH

The Claim

ImmunityBio's drug N-803 (anktiva) is being investigated or has demonstrated efficacy in treating, curing, or preventing cancer types beyond bladder cancer.

Verified by Lenz ·

The Short Version

ImmunityBio's N-803 (Anktiva) is actively being investigated in multiple cancer types beyond bladder cancer, including pancreatic cancer, non-small cell lung cancer, glioblastoma, and other advanced solid tumors, as confirmed by ClinicalTrials.gov registrations and NCI-sponsored trials. Preliminary efficacy signals in NSCLC have been reported, though definitive Phase 3 proof of efficacy beyond bladder cancer has not yet been established. The claim's "being investigated" component is firmly supported by high-authority sources.

Caveats

  • Most non-bladder cancer studies are early-phase or still recruiting; 'demonstrated efficacy' in these indications reflects preliminary signals, not confirmed clinical benefit from Phase 3 trials.
  • The claim's reference to 'curing' or 'preventing' cancer beyond bladder is not supported by any available evidence; current data address treatment response and survival endpoints only.
  • Regulatory approvals for N-803 beyond bladder cancer are limited to provisional, jurisdiction-specific authorizations (e.g., Saudi conditional accelerated approval in NSCLC) and do not represent broad regulatory consensus.

The Receipts

  1. QUILT-88: Pancreatic Cancer Study with N-803

    ClinicalTrials.gov

  2. Lung-MAP: A Master Protocol to Evaluate Immunotherapy Combinations in Patients With Previously Untreated, Metastatic Non-small Cell Lung Cancer Without Actionable Oncogenic Driver Mutations

    ClinicalTrials.gov

  3. QUILT-3.055: Study of Combination Therapy With N-803 and Cemiplimab in PD1 Checkpoint Inhibitor Experienced Subjects With Advanced Solid Tumors

    ClinicalTrials.gov

  4. Lung-MAP: Anktiva and Pembrolizumab for NSCLC (S1900G)

    National Cancer Institute

  5. National Cancer Institute Selects ImmunityBio's N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy

    Friends of Cancer Research

  6. N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | ClinicalTrials.gov

    ClinicalTrials.gov

  7. Search Results for N-803 Cancer

    PubMed

  8. Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies - PMC

    PMC

  9. ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

    ImmunityBio, Inc.

  10. ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled With FDA to Discuss Registration Path for Anktiva in Lung Cancer

    BioSpace

+ 11 more sources — see the full list on Lenz

Filed Under

AnktivaBladder CancerImmunityBio

More Fact Checks